Estimated ALT changes in participants with presumed NAFLD were 15.5% vs +10.6% with semaglutide vs placebo group, respectively (Table 1)
"We found the benefits to be consistent across different drugs, trial designs and patient groups
GLP-1 drugs have obviously been all the rage for weight loss, and there has been some off-label use of them to treat liver disease like MASH, but in the Phase III ESSENCE trial, after 72 weeks, 63% of patients on Wegovy saw their steatohepatitis resolved without any worsening of fibrosis, compared to just 34% with placebo
Use Routine Check-Ups to Stay Safe Regular check-ups and lab tests can help monitor health while taking Semaglutide
Research Applications BPC-157 is used in research models studying tissue repair mechanisms, anti-inflammatory pathways, gastrointestinal mucosal recovery, and tendon-bone junction healing
When to Be Concerned Frequent urination is not always a cause for alarm